Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Protein Atlas Maps the Inner Workings of Cells

The accumulation of misfolded proteins can cause disease. Knowing how proteins behave inside human cells can be a tool used to search for the origins of diseases such as dementia and many cancers. Now, researchers at the University of Cambridge led by Tuomas K

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The accumulation of misfolded proteins can cause disease. Knowing how proteins behave inside human cells can be a tool used to search for the origins of diseases such as dementia and many cancers. Now, researchers at the University of Cambridge led by Tuomas Knowles, PhD, professor of physical chemistry and biophysics proteins, have developed an atlas of proteins describing how they behave inside human cells. The atlas has allowed the researchers to discover new proteins inside cells that are responsible for a range of important bodily functions.

The atlas and the team’s findings are published in Nature Communications in an article titled, “Protein Condensate Atlas from predictive models of heteromolecular condensate composition.”

The team focused on a droplet-like part of the cell called a condensate which is a meeting hub for proteins to go and organize themselves. These hubs are also key sites where disease processes start.

The predictions are available with the paper so researchers around the globe can explore their protein targets of interest and any surrounding condensate systems.

“This model has allowed us to discover new components in membrane-less compartments in biology as well as discover new principles underlying their function,” said Knowles, who led the research.

“To date we have not had a comprehensive map of which proteins go together into which condensates, but in our work we provide a first such atlas,” said Knowles.

The rules directing proteins inside cells are not completely understood so the team decided to build this atlas to predict which proteins meet inside condensates.

“What motivated this research was the desire to understand the full complexity of protein condensates and to go a layer deeper than what scientists have researched so far,” said Kadi Liis Saar, PhD, first author on this research and a postdoctoral fellow at the Centre for Misfolding Diseases.

The researchers used large databases, such as StringDB and BioGRID, which contain data on many aspects of cells, along with more in-depth case studies about individual condensates.

“With this atlas, we can make predictions about every single protein in a cell, where exactly it would be found, and what sorts of other proteins it interacts with,” commented Saar. “We hope that this generates opportunities for researchers and opens up new possibilities for intervention in diseases associated with aberrant condensate formation.”

The AI found proteins present in the model cell that had never been observed before. If these proteins are now found in a lab then this is a good indicator that the AI is accurate.

“In our study, we discovered proteins within condensates that have never been seen there before. These proteins are involved in important functions in the body, such as the distribution of fat, the creation of actin inside cells, and the creation of new proteins. These proteins were not detected in the previous study that we used as our training set.

“We hope these data will enable new discoveries about the biological roles of condensates as well as the biophysical drivers behind condensate formation.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →